Ask AI
EV 302 Responder Analysis
EV-302/KEYNOTE-A39: Exploratory Analysis of Responders to Enfortumab Vedotin + Pembrolizumab vs Chemotherapy for Previously Untreated Advanced or Metastatic Urothelial Carcinoma

Released: June 05, 2025

Expiration: December 04, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: June 05, 2025

Expiration: December 04, 2025